Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01075217 · ClinicalTrials.gov registry record · Phase 4
Isovue in Peripheral Digital Subtraction Angiography (DSA)
A Phase 4 study of Peripheral Arterial Occlusive Disease, sponsored by Bracco Diagnostics.
- Completed
- Registry status
- Phase 4
- Development phase
- 174
- Enrollment target
- 1
- Study location
NCT01075217 is a Phase 4 study of Peripheral Arterial Occlusive Disease that has completed, run by Bracco Diagnostics. The registered enrollment target is 174 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01075217, a Phase 4 study of Peripheral Arterial Occlusive Disease, has completed, sponsored by Bracco Diagnostics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 174 participants
- Enrollment target
- 1
- Study location
Study Summary
No significant differences is expected in observed motion artifacts, heat or pain reported during peripheral DSA performed for diagnostic and/or endovascular therapeutic purposes.
Conditions Studied
Interventions
- DRUG iopamidol
- DRUG iodixanol
Study Locations (1)
New Jersey
- Bracco Diagnostics - Princeton
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 174 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01075217
The ClinicalTrials.gov registry entry for NCT01075217 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 174 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bracco Diagnostics, which has 37 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Peripheral Arterial Occlusive Disease appearing as the primary indexed condition, and to 2 interventions - of which iopamidol is the first listed.
NCT01075217 reports 1 study location spanning 1 distinct geographic area - top geographies include New Jersey.
Frequently Asked Questions
What is clinical trial NCT01075217 about?
NCT01075217 is a clinical study titled "Isovue in Peripheral Digital Subtraction Angiography (DSA)". No significant differences is expected in observed motion artifacts, heat or pain reported during peripheral DSA performed for diagnostic and/or endovascular therapeutic purposes.
What is the current status of trial NCT01075217?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 174 participants. The study started on 2010-04. Estimated completion is 2011-12.
What conditions does trial NCT01075217 study?
This clinical trial studies the following conditions: Peripheral Arterial Occlusive Disease.
What interventions are being tested in trial NCT01075217?
The interventions under investigation include: iopamidol (DRUG), iodixanol (DRUG).
Who is sponsoring clinical trial NCT01075217?
This trial is sponsored by Bracco Diagnostics, which has 37 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01075217 being conducted?
This trial has 1 study location across New Jersey. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Peripheral Arterial Occlusive Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.